Extragonadal germ cell tumors of the mediastinum and retroperitoneum: Results from an international analysis

Carsten Bokemeyer, Craig R. Nichols, Jean P. Droz, Hans J. Schmoll, Alan Horwich, Arthur Gerl, Sophie D. Fossa, Jörg Beyer, Jörg Pont, Lothar Kanz, Lawrence Einhorn, Jörg T. Hartmann

Research output: Contribution to journalArticle

264 Citations (Scopus)

Abstract

Purpose: To characterize the clinical and biologic features of extragonadal germ cell tumor (EGCT) and to determine the overall outcome with currently available treatment strategies. Patients and Methods: Of an unselected population of 635 consecutive patients treated from 1975 through 1996 at 11 cancer centers, 341 patients (54%) had primary mediastinal EGCT, and 283 patients (45%) had retroperitoneal EGCT. Five hundred twenty-four patients (83%) had a nonseminomatous germ cell tumor (GCT), and 104 patients (16%) had a seminomatous histology. Results: After platinum-based induction chemotherapy with or without secondary surgery, 141 patients (49%) with mediastinal nonseminomas (median follow-up, 19 months; range, 1 to 178 months) and 144 patients (63%) with retroperitoneal nonseminoma (median follow-up, 29 months; range, 1 to 203 months) are alive (P = .0006). In contrast, the overall survival rate for patients with a seminomatous EGCT is 88%, with no difference between patients with mediastinal or retroperitoneal tumor location (median follow-up, 49 months; range, 4 to 193 months; respective 70 months; range, 1 to 211 months). A significantly lower progression-free survival rate was found in seminoma patients treated with initial radiotherapy alone compared with chemotherapy. Nonseminomatous histology, presence of nonpulmonary visceral metastases, primary mediastinal GCT location, and elevated beta-human chorionic gonadotropin were independent prognostic factors for shorter survival. Hematologic malignancies (n = 17) occurred without exception in patients with primary mediastinal nonseminoma. Sixteen patients developed a metachronous testicular cancer despite the use of platinum-based chemotherapy. Conclusion: Whereas patients with pure seminomatous EGCT histology have a long-term chance of cure of almost 90% irrespective of the primary tumor site, 45% of patients with mediastinal nonseminomas are alive at 5 years. This outcome is clearly inferior compared with patients with nonseminomatous retroperitoneal primary tumors.

Original languageEnglish
Pages (from-to)1864-1873
Number of pages10
JournalJournal of Clinical Oncology
Volume20
Issue number7
DOIs
StatePublished - Apr 1 2002

Fingerprint

Germ Cell and Embryonal Neoplasms
Mediastinum
Histology
Platinum
Neoplasms
Survival Rate
Drug Therapy
Seminoma
Induction Chemotherapy
Testicular Neoplasms
Hematologic Neoplasms
Chorionic Gonadotropin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bokemeyer, C., Nichols, C. R., Droz, J. P., Schmoll, H. J., Horwich, A., Gerl, A., ... Hartmann, J. T. (2002). Extragonadal germ cell tumors of the mediastinum and retroperitoneum: Results from an international analysis. Journal of Clinical Oncology, 20(7), 1864-1873. https://doi.org/10.1200/JCO.2002.07.062

Extragonadal germ cell tumors of the mediastinum and retroperitoneum : Results from an international analysis. / Bokemeyer, Carsten; Nichols, Craig R.; Droz, Jean P.; Schmoll, Hans J.; Horwich, Alan; Gerl, Arthur; Fossa, Sophie D.; Beyer, Jörg; Pont, Jörg; Kanz, Lothar; Einhorn, Lawrence; Hartmann, Jörg T.

In: Journal of Clinical Oncology, Vol. 20, No. 7, 01.04.2002, p. 1864-1873.

Research output: Contribution to journalArticle

Bokemeyer, C, Nichols, CR, Droz, JP, Schmoll, HJ, Horwich, A, Gerl, A, Fossa, SD, Beyer, J, Pont, J, Kanz, L, Einhorn, L & Hartmann, JT 2002, 'Extragonadal germ cell tumors of the mediastinum and retroperitoneum: Results from an international analysis', Journal of Clinical Oncology, vol. 20, no. 7, pp. 1864-1873. https://doi.org/10.1200/JCO.2002.07.062
Bokemeyer, Carsten ; Nichols, Craig R. ; Droz, Jean P. ; Schmoll, Hans J. ; Horwich, Alan ; Gerl, Arthur ; Fossa, Sophie D. ; Beyer, Jörg ; Pont, Jörg ; Kanz, Lothar ; Einhorn, Lawrence ; Hartmann, Jörg T. / Extragonadal germ cell tumors of the mediastinum and retroperitoneum : Results from an international analysis. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 7. pp. 1864-1873.
@article{76c558d34d7b4a2c8038516fca6d6cc9,
title = "Extragonadal germ cell tumors of the mediastinum and retroperitoneum: Results from an international analysis",
abstract = "Purpose: To characterize the clinical and biologic features of extragonadal germ cell tumor (EGCT) and to determine the overall outcome with currently available treatment strategies. Patients and Methods: Of an unselected population of 635 consecutive patients treated from 1975 through 1996 at 11 cancer centers, 341 patients (54{\%}) had primary mediastinal EGCT, and 283 patients (45{\%}) had retroperitoneal EGCT. Five hundred twenty-four patients (83{\%}) had a nonseminomatous germ cell tumor (GCT), and 104 patients (16{\%}) had a seminomatous histology. Results: After platinum-based induction chemotherapy with or without secondary surgery, 141 patients (49{\%}) with mediastinal nonseminomas (median follow-up, 19 months; range, 1 to 178 months) and 144 patients (63{\%}) with retroperitoneal nonseminoma (median follow-up, 29 months; range, 1 to 203 months) are alive (P = .0006). In contrast, the overall survival rate for patients with a seminomatous EGCT is 88{\%}, with no difference between patients with mediastinal or retroperitoneal tumor location (median follow-up, 49 months; range, 4 to 193 months; respective 70 months; range, 1 to 211 months). A significantly lower progression-free survival rate was found in seminoma patients treated with initial radiotherapy alone compared with chemotherapy. Nonseminomatous histology, presence of nonpulmonary visceral metastases, primary mediastinal GCT location, and elevated beta-human chorionic gonadotropin were independent prognostic factors for shorter survival. Hematologic malignancies (n = 17) occurred without exception in patients with primary mediastinal nonseminoma. Sixteen patients developed a metachronous testicular cancer despite the use of platinum-based chemotherapy. Conclusion: Whereas patients with pure seminomatous EGCT histology have a long-term chance of cure of almost 90{\%} irrespective of the primary tumor site, 45{\%} of patients with mediastinal nonseminomas are alive at 5 years. This outcome is clearly inferior compared with patients with nonseminomatous retroperitoneal primary tumors.",
author = "Carsten Bokemeyer and Nichols, {Craig R.} and Droz, {Jean P.} and Schmoll, {Hans J.} and Alan Horwich and Arthur Gerl and Fossa, {Sophie D.} and J{\"o}rg Beyer and J{\"o}rg Pont and Lothar Kanz and Lawrence Einhorn and Hartmann, {J{\"o}rg T.}",
year = "2002",
month = "4",
day = "1",
doi = "10.1200/JCO.2002.07.062",
language = "English",
volume = "20",
pages = "1864--1873",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Extragonadal germ cell tumors of the mediastinum and retroperitoneum

T2 - Results from an international analysis

AU - Bokemeyer, Carsten

AU - Nichols, Craig R.

AU - Droz, Jean P.

AU - Schmoll, Hans J.

AU - Horwich, Alan

AU - Gerl, Arthur

AU - Fossa, Sophie D.

AU - Beyer, Jörg

AU - Pont, Jörg

AU - Kanz, Lothar

AU - Einhorn, Lawrence

AU - Hartmann, Jörg T.

PY - 2002/4/1

Y1 - 2002/4/1

N2 - Purpose: To characterize the clinical and biologic features of extragonadal germ cell tumor (EGCT) and to determine the overall outcome with currently available treatment strategies. Patients and Methods: Of an unselected population of 635 consecutive patients treated from 1975 through 1996 at 11 cancer centers, 341 patients (54%) had primary mediastinal EGCT, and 283 patients (45%) had retroperitoneal EGCT. Five hundred twenty-four patients (83%) had a nonseminomatous germ cell tumor (GCT), and 104 patients (16%) had a seminomatous histology. Results: After platinum-based induction chemotherapy with or without secondary surgery, 141 patients (49%) with mediastinal nonseminomas (median follow-up, 19 months; range, 1 to 178 months) and 144 patients (63%) with retroperitoneal nonseminoma (median follow-up, 29 months; range, 1 to 203 months) are alive (P = .0006). In contrast, the overall survival rate for patients with a seminomatous EGCT is 88%, with no difference between patients with mediastinal or retroperitoneal tumor location (median follow-up, 49 months; range, 4 to 193 months; respective 70 months; range, 1 to 211 months). A significantly lower progression-free survival rate was found in seminoma patients treated with initial radiotherapy alone compared with chemotherapy. Nonseminomatous histology, presence of nonpulmonary visceral metastases, primary mediastinal GCT location, and elevated beta-human chorionic gonadotropin were independent prognostic factors for shorter survival. Hematologic malignancies (n = 17) occurred without exception in patients with primary mediastinal nonseminoma. Sixteen patients developed a metachronous testicular cancer despite the use of platinum-based chemotherapy. Conclusion: Whereas patients with pure seminomatous EGCT histology have a long-term chance of cure of almost 90% irrespective of the primary tumor site, 45% of patients with mediastinal nonseminomas are alive at 5 years. This outcome is clearly inferior compared with patients with nonseminomatous retroperitoneal primary tumors.

AB - Purpose: To characterize the clinical and biologic features of extragonadal germ cell tumor (EGCT) and to determine the overall outcome with currently available treatment strategies. Patients and Methods: Of an unselected population of 635 consecutive patients treated from 1975 through 1996 at 11 cancer centers, 341 patients (54%) had primary mediastinal EGCT, and 283 patients (45%) had retroperitoneal EGCT. Five hundred twenty-four patients (83%) had a nonseminomatous germ cell tumor (GCT), and 104 patients (16%) had a seminomatous histology. Results: After platinum-based induction chemotherapy with or without secondary surgery, 141 patients (49%) with mediastinal nonseminomas (median follow-up, 19 months; range, 1 to 178 months) and 144 patients (63%) with retroperitoneal nonseminoma (median follow-up, 29 months; range, 1 to 203 months) are alive (P = .0006). In contrast, the overall survival rate for patients with a seminomatous EGCT is 88%, with no difference between patients with mediastinal or retroperitoneal tumor location (median follow-up, 49 months; range, 4 to 193 months; respective 70 months; range, 1 to 211 months). A significantly lower progression-free survival rate was found in seminoma patients treated with initial radiotherapy alone compared with chemotherapy. Nonseminomatous histology, presence of nonpulmonary visceral metastases, primary mediastinal GCT location, and elevated beta-human chorionic gonadotropin were independent prognostic factors for shorter survival. Hematologic malignancies (n = 17) occurred without exception in patients with primary mediastinal nonseminoma. Sixteen patients developed a metachronous testicular cancer despite the use of platinum-based chemotherapy. Conclusion: Whereas patients with pure seminomatous EGCT histology have a long-term chance of cure of almost 90% irrespective of the primary tumor site, 45% of patients with mediastinal nonseminomas are alive at 5 years. This outcome is clearly inferior compared with patients with nonseminomatous retroperitoneal primary tumors.

UR - http://www.scopus.com/inward/record.url?scp=0036533845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036533845&partnerID=8YFLogxK

U2 - 10.1200/JCO.2002.07.062

DO - 10.1200/JCO.2002.07.062

M3 - Article

C2 - 11919246

AN - SCOPUS:0036533845

VL - 20

SP - 1864

EP - 1873

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -